These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 12881196)
61. Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model. Pan XQ; Wang H; Lee RJ Pharm Res; 2003 Mar; 20(3):417-22. PubMed ID: 12669962 [TBL] [Abstract][Full Text] [Related]
62. Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload. Wang Y; Fan S; Zhong W; Zhou X; Li S Int J Mol Sci; 2017 Aug; 18(9):. PubMed ID: 28841157 [TBL] [Abstract][Full Text] [Related]
63. Tumor targeting using anti-her2 immunoliposomes. Park JW; Kirpotin DB; Hong K; Shalaby R; Shao Y; Nielsen UB; Marks JD; Papahadjopoulos D; Benz CC J Control Release; 2001 Jul; 74(1-3):95-113. PubMed ID: 11489487 [TBL] [Abstract][Full Text] [Related]
64. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition. Gao M; Xu Y; Qiu L J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110 [TBL] [Abstract][Full Text] [Related]
65. Inhibition of P-glycoprotein and increasing of drug-sensitivity of a human carcinoma cell line (KB-A-1) by an antisense oligodeoxynucleotide-doxorubicin conjugate in vitro. Ren Y; Wei D; Zhan X Biotechnol Appl Biochem; 2005 Apr; 41(Pt 2):137-43. PubMed ID: 15202936 [TBL] [Abstract][Full Text] [Related]
66. HPMA copolymer-bound doxorubicin induces immunogenic tumor cell death. Sirova M; Kabesova M; Kovar L; Etrych T; Strohalm J; Ulbrich K; Rihova B Curr Med Chem; 2013; 20(38):4815-26. PubMed ID: 24083609 [TBL] [Abstract][Full Text] [Related]
67. Doxorubicin: monoclonal antibody conjugate for therapy of human cervical carcinoma. Yeh MY; Roffler SR; Yu MH Int J Cancer; 1992 May; 51(2):274-82. PubMed ID: 1568795 [TBL] [Abstract][Full Text] [Related]
68. Carboxymethyl dextran-cyclodextrin conjugate as the carrier of doxorubicin. Sivasubramanian M; Thambi T; Deepagan VG; Saravanakumar G; Ko H; Kang YM; Park JH J Nanosci Nanotechnol; 2013 Nov; 13(11):7271-8. PubMed ID: 24245242 [TBL] [Abstract][Full Text] [Related]
69. Lysyl oxidase like-4 monoclonal antibody demonstrates therapeutic effect against head and neck squamous cell carcinoma cells and xenografts. Görögh T; Quabius ES; Heidebrecht H; Nagy A; Muffels T; Haag J; Ambrosch P; Hoffmann M Int J Cancer; 2016 May; 138(10):2529-38. PubMed ID: 26756583 [TBL] [Abstract][Full Text] [Related]
70. RON receptor tyrosine kinase as a target for delivery of chemodrugs by antibody directed pathway for cancer cell cytotoxicity. Guin S; Yao HP; Wang MH Mol Pharm; 2010 Apr; 7(2):386-97. PubMed ID: 20039696 [TBL] [Abstract][Full Text] [Related]
71. Novel doxorubicin-monoclonal anti-carcinoembryonic antigen antibody immunoconjugate activity in vitro. Lau A; Bérubé G; Ford CH; Gallant M Bioorg Med Chem; 1995 Oct; 3(10):1305-12. PubMed ID: 8564396 [TBL] [Abstract][Full Text] [Related]
72. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Park JW; Hong K; Kirpotin DB; Colbern G; Shalaby R; Baselga J; Shao Y; Nielsen UB; Marks JD; Moore D; Papahadjopoulos D; Benz CC Clin Cancer Res; 2002 Apr; 8(4):1172-81. PubMed ID: 11948130 [TBL] [Abstract][Full Text] [Related]
73. Quantitative characterization of in vitro bystander effect of antibody-drug conjugates. Singh AP; Sharma S; Shah DK J Pharmacokinet Pharmacodyn; 2016 Dec; 43(6):567-582. PubMed ID: 27670282 [TBL] [Abstract][Full Text] [Related]
74. A personal perspective of the development and validation of a phase-specific antibody-drug conjugate cytotoxicity potency assay. Wilson R Bioanalysis; 2013 May; 5(9):1083-97. PubMed ID: 23641698 [TBL] [Abstract][Full Text] [Related]
75. Monoclonal antibody-mediated drug targeting to choroidal neovascularization in the rat. Kamizuru H; Kimura H; Yasukawa T; Tabata Y; Honda Y; Ogura Y Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2664-72. PubMed ID: 11581214 [TBL] [Abstract][Full Text] [Related]
76. Novel adenoviral gene delivery system targeted against head and neck cancer. Li D; Guang W; Abuzeid WM; Roy S; Gao GP; Sauk JJ; O'Malley BW Laryngoscope; 2008 Apr; 118(4):650-8. PubMed ID: 18176343 [TBL] [Abstract][Full Text] [Related]
77. Poly(amidoamine) Dendrimer-Doxorubicin Conjugates: In Vitro Characteristics and Pseudosolution Formulation in Pressurized Metered-Dose Inhalers. Zhong Q; da Rocha SR Mol Pharm; 2016 Mar; 13(3):1058-72. PubMed ID: 26832992 [TBL] [Abstract][Full Text] [Related]
78. In vitro and in vivo activities of a doxorubicin prodrug in combination with monoclonal antibody beta-lactamase conjugates. Svensson HP; Vrudhula VM; Emswiler JE; MacMaster JF; Cosand WL; Senter PD; Wallace PM Cancer Res; 1995 Jun; 55(11):2357-65. PubMed ID: 7757987 [TBL] [Abstract][Full Text] [Related]
79. An Antibody-Drug Conjugate Directed against Lymphocyte Antigen 6 Complex, Locus E (LY6E) Provides Robust Tumor Killing in a Wide Range of Solid Tumor Malignancies. Asundi J; Crocker L; Tremayne J; Chang P; Sakanaka C; Tanguay J; Spencer S; Chalasani S; Luis E; Gascoigne K; Desai R; Raja R; Friedman BA; Haverty PM; Polakis P; Firestein R Clin Cancer Res; 2015 Jul; 21(14):3252-62. PubMed ID: 25862760 [TBL] [Abstract][Full Text] [Related]
80. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Staudacher AH; Brown MP Br J Cancer; 2017 Dec; 117(12):1736-1742. PubMed ID: 29065110 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]